Company Filing History:
4 out of 234 
2 out of 206 
2 out of 3,685 
Years Active: 1995-2008
Title: The Innovations of Robert F. Kaltenbach
Introduction
Robert F. Kaltenbach is a notable inventor based in Wilmington, Delaware. He holds a total of nine patents, showcasing his significant contributions to the field of pharmaceuticals. His work primarily focuses on selective estrogen receptor modulators, which have important implications for treating various estrogen-stimulated diseases.
Latest Patents
Kaltenbach's latest patents include innovative triphenylethylene derivatives. One of his inventions, 3-{4-[6-(3-Methoxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid, serves as a selective estrogen receptor modulator. This invention provides methods for treating diseases such as breast, uterine, ovarian, prostate, and colon cancer, as well as osteoporosis, endometriosis, Alzheimer's disease, and type II diabetes. Another patent features the compound 5-{2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-vinyl}-1H-tetrazole, which also functions as a selective estrogen receptor modulator with similar therapeutic applications.
Career Highlights
Throughout his career, Kaltenbach has worked with prominent companies in the pharmaceutical industry. He has been associated with Bristol-Myers Squibb Pharma Company and the DuPont Merck Pharmaceutical Company. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Kaltenbach has collaborated with notable colleagues, including George L. Trainor and Simon P. Robinson. These partnerships have likely enhanced his research and development efforts in the pharmaceutical sector.
Conclusion
Robert F. Kaltenbach's contributions to the field of pharmaceuticals through his patents on selective estrogen receptor modulators highlight his innovative spirit and dedication to improving healthcare. His work continues to impact the treatment of various diseases, showcasing the importance of innovation in medicine.